Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegilodecakin + FOLFOX
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
pegilodecakin + FOLFOX is an experimental combination therapy investigated for metastatic pancreatic ductal adenocarcinoma (PDAC), especially as second-line treatment for patients progressing after gemcitabine-based therapy. Pegilodecakin (AM0010) is a pegylated recombinant human interleukin-10 (IL-10) designed to stimulate anti-tumor immunity, specifically enhancing CD8+ T cell survival, proliferation, and cytotoxic activity. FOLFOX is a chemotherapy regimen that combines folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin, exerting cytotoxic effects via DNA synthesis inhibition and DNA cross-linking. The combination was designed to synergize chemotherapy-induced immunogenic cell death with IL-10-mediated immune activation; however, large phase 3 clinical trials did not demonstrate an improvement in overall survival or progression-free survival compared to FOLFOX alone, although immunomodulatory effects (e.g., increases in IFN-γ, IL-18, granzyme B, and reduction of TGF-β) were observed. Toxicities were manageable, though anemia and thrombocytopenia were more frequent with the combination[2][4][1][3][5].
- Other names
- pegilodecakin + FOLFOX
02
Targets
IL10RA (Interleukin-10 Receptor)
Beyond the preview
Go deeper on pegilodecakin + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegilodecakin + FOLFOX.